|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.22 USD | -0.02% |
|
+1.89% | +6.48% |
| 06-16 | GSK's Exdensur Wins Canadian Approval for Severe Asthma, Nasal Polyps | MT |
| 06-16 | Saudi Chemical Co. Secures New Medical Marketing Services Deal from GSK Unit | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1,007B | |||||
| 567B | |||||
| 392B | |||||
| 328B | |||||
| 277B |
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
- Charts GSK plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
